These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 24138302)

  • 1. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
    Luke JJ; Ott PA
    Expert Opin Pharmacother; 2013 Dec; 14(18):2457-62. PubMed ID: 24138302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
    Menzies AM; Long GV
    Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic options in systemic treatment of advanced cutaneous melanoma.
    Mackiewicz-Wysocka M; Zolnierek J; Wysocki PJ
    Expert Opin Investig Drugs; 2013 Feb; 22(2):181-90. PubMed ID: 23215674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma Treatments: Advances and Mechanisms.
    Marzuka A; Huang L; Theodosakis N; Bosenberg M
    J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase inhibitors in melanoma.
    Eigentler TK; Meier F; Garbe C
    Expert Opin Pharmacother; 2013 Nov; 14(16):2195-201. PubMed ID: 23992377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting oncogenic drivers and the immune system in melanoma.
    McArthur GA; Ribas A
    J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
    Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
    Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis.
    An Q; Liu Z
    BMC Cancer; 2019 Jan; 19(1):43. PubMed ID: 30626368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF inhibitors and melanoma.
    Flaherty KT
    Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
    Amann VC; Hoffmann D; Mangana J; Dummer R; Goldinger SM
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1638-1640. PubMed ID: 28401596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
    Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
    Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.
    Zhou AY; Johnson DB
    Am J Clin Dermatol; 2018 Apr; 19(2):181-193. PubMed ID: 28861871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives.
    Malissen N; Grob JJ
    Drugs; 2018 Aug; 78(12):1197-1209. PubMed ID: 30097888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
    Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.
    Tétu P; Baroudjian B; Lebbe C
    Curr Opin Oncol; 2020 Mar; 32(2):85-90. PubMed ID: 31895121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.